Can yervoy's severe side effects be life threatening?

What are the potential severe side effects of Yervoy?

Ipilimumab, marketed as Yervoy by Bristol Myers Squibb, is a monoclonal antibody used to treat melanoma and other cancers [1]. Like many cancer treatments, Yervoy can cause severe side effects, some of which may be life-threatening.

What is the risk of life-threatening severe side effects with Yervoy?

Studies have shown that Yervoy can cause life-threatening side effects in approximately 1% to 5% of patients [2]. The most common severe side effects include:

* Colitis (inflammation of the colon): This can be severe and may cause life-threatening damage to the colon [3].
* Hypophysitis (inflammation of the pituitary gland): This can lead to life-threatening hormonal imbalances.
* Hepatitis (inflammation of the liver): This can cause severe liver damage and potentially life-threatening complications.
* Nephritis (inflammation of the kidneys): This can cause severe kidney damage and potentially life-threatening complications.

Why do severe side effects occur with Yervoy?

Yervoy targets the CTLA-4 protein on immune cells, unleashing the immune system to attack cancer cells, but also potentially attacking healthy tissue [4]. This can lead to severe autoimmune reactions, such as the ones mentioned above.

What happens if severe side effects occur with Yervoy?

If severe side effects occur with Yervoy, patients may experience symptoms such as abdominal pain, bloody stools, diarrhea, severe headache, and vomiting. Patients should seek immediate medical attention if they experience any of these symptoms.

What can be done to prevent or manage severe side effects of Yervoy?

To minimize the risk of severe side effects, patients should follow their doctor's instructions carefully and attend regular follow-up appointments. If severe side effects do occur, prompt treatment can reduce the risk of life-threatening complications.

References:

[1] DrugPatentWatch.com. Ipilimumab. https://www.drugpatentwatch.com/Drug/Ipilimumab

[2] Bristol Myers Squibb Company. Yervoy (Ipilimumab) Prescribing Information. 2020.

[3] Weber, J. S., et al. (2012). Phase I/II study of ipilimumab for patients with metastatic melanoma. Journal of Clinical Oncology, 30(21), 2651–2659.

[4] Hodi, F. S., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363(8), 711–723.

Bristol Myers Squibb Company: https://www.bms.com/

DrugPatentWatch.com: https://www.drugpatentwatch.com/